臨床外科62巻9号

2007年09月発行

特集 多発肝転移をめぐって

大腸癌肝転移に対する全身化学療法の役割

著者： 山崎健太郎¹ 吉野孝之¹

所属機関： ¹静岡県立静岡がんセンター消化器内科

ページ範囲：P.1205 - P.1209

要旨：遠隔転移を伴う消化器癌の多くは根治切除が不能であり，全身化学療法の適応である．しかし，大腸癌肝転移の切除後の5年生存率は30～50％で，転移巣切除によって治癒を期待できる．したがって，現在の大腸癌肝転移に対する標準治療は切除可能であれば外科的切除，切除不能であれば全身化学療法である．ただし，初回診断時に切除不能な場合でも，化学療法の奏効後に治癒切除が可能となり，長期生存が期待できる症例も存在する．新しい試みとして，治癒切除率の向上を目的とした術前化学療法や術後補助療法，周術期化学療法などがある．本稿では大腸癌肝転移症例に対する全身化学療法の意義について海外の報告をもとに概説する．

参考文献

1）Hurwitz H, Fehrenbacher L, Novotny W, et al：Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350：2335-2342, 2004

2）Cassidy J, Clarke S, Rubio ED, et al：First efficacy and safety results from XELOX-1/NO16966, a randomised 2×2 factorial phase Ⅲ trial of XELOX vs. FOLFOX4 1 bevacizumab or placebo in first-line metastatic colorectal cancer（MCRC）. （abstract）Annals of Oncology 17：LBA3, 2006

3）Bismuth H, Adam R, Lévi F, et al：Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann Surg 22：509-520, 1996

4）Goldberg RM, Sargent DJ, Morton RF, et al：A randomized controlled trial of fluorouracil plus leucovorin, irinotecan, and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J Clin Oncol 22：23-30, 2004

5）Delaunoit T, Alberts SR, Sargent DJ, et al：Chemotherapy permits resection of metastatic colorectal cancer：experience from Intergroup N9741. Ann Oncol 16：425-429, 2005

6）Tournigand C, Andre T, Achille E, et al：FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer：a randomized GERCOR study. J Clin Oncol 22：229-237, 2004

7）Folprecht G, Grothey A, Alberts S, et al：Neoadjuvant treatment of unresectable colorectal liver metastases：correlation between tumour response and resection rates. Ann Oncol 16：1311-1319, 2005

8）Rubbia-Brandt L, Giostra E, Brezault C, et al：Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery. Ann Oncol 18：299-304, 2007

9）Andre T, Tabernero J, Van Cutsem E, et al：PhaseⅡ study with cetuximab plus FOLFOX-4 in first-line setting for epidermal growth factor receptor（EGFR）-expressing metastatic colorectal cancer（mCRC）：Final results.（abstract）Gastrointestinal Cancer Symposium 334, 2007

10）Bokemeyer C, Bondarenko I, Makhson A, et al：Cetuximab plus 5-FU/FA/oxaliplatin（FOLFOX-4）versus FOLFOX-4 in the first-line treatment of metastatic colorectal cancer（mCRC）：OPUS, a randomized phaseⅡ study.（abstraact）ASCO Annual Meeting 4035, 2007

11）Van Cutsem E, Nowacki M, Lang I, et al：Randomized phase Ⅲ study of irinotecan and 5-FU/FA with or without cetuximab in the first-line treatment of patients with metastatic colorectal cancer（mCRC）：The CRYSTAL trial.（abstraact）ASCO Annual Meeting 4000, 2007

12）Fuchs C, Marshall J, Mitchell E, et al：Updated results of BICC-C study comparing first-line irinotecan/fluoropymidine combinations with or without celecoxib in mCRC：Updated efficacy data（abstract）. ASCO Annual Meeting 4027, 2007

13）Kabbinavar FF, Schulz J, McCleod M, et al：Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer：results of a randomized phaseⅡ trial. J Clin Oncol 23：3697-3705, 2005

14）Vauthey JN, Pawlik TM, Ribero D, et al：Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24：2065-2072, 2006

15）Portier G, Elias D, Bouche O, et al：Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases：FFCD ACHBTH AURC 9002 trial. J Clin Oncol 24：4976-4982, 2006

16）Nordlinger B, Sorbye H, Collette L, et al：Final results of the EORTC Intergroup randomized phase Ⅲ study 40983［EPOC］evaluating the benefit of peri-operative（abstract）. ASCO Annual Meeting LBA5, 2007